Effector cells derived from naive T cells used in tumor immunotherapy of mice bearing B16 melanoma

被引:1
|
作者
Wen Ming [1 ,2 ]
Xu Weili [4 ]
Ren Lili [3 ]
Gao Fei [6 ,7 ]
Cui Naipeng [2 ]
Wen Junye [1 ]
Li Xinjiang [5 ]
Lin Lin [5 ]
Ma Zhenfeng [2 ]
Chen Baoping [2 ]
Cai Jianhui [6 ,7 ]
机构
[1] Hebei Med Univ, Dept Surg, Shijiazhuang 050017, Hebei, Peoples R China
[2] Hebei Univ, Dept Surg Oncol, Affiliated Hosp, Baoding 071000, Hebei, Peoples R China
[3] Hebei Univ, Dept Med Oncol, Affiliated Hosp, Baoding 071000, Hebei, Peoples R China
[4] Hebei Med Univ, Dept Pediat Surg, Hosp 2, Shijiazhuang 050000, Hebei, Peoples R China
[5] Hebei Med Univ, Dept Surg, Hosp 2, Shijiazhuang 050000, Hebei, Peoples R China
[6] Hebei Med Univ, Teaching & Res Sect, Shijiazhuang 050017, Hebei, Peoples R China
[7] Hebei Gen Hosp, Dept Surg, Dept Oncol & Immunotherapy, Shijiazhuang 050051, Hebei, Peoples R China
关键词
naive T cell; pooled T cells; cytotoxic T lymphocyte; melanoma; immunotherapy; adoptive transfer; IN-VIVO; METASTATIC MELANOMA; ADOPTIVE TRANSFER; DENDRITIC CELLS; PHASE-I; CANCER; MEMORY; LYMPHOCYTES; DETERMINES; REGRESSION;
D O I
10.3760/cma.j.issn.0366-6999.20123364
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Adoptive cell transfer (ACT) immunotherapy has been used clinically for years to treat malignancies. Improving the killing efficiency of effector cells, such as tumor-specific cytotoxic T lymphocytes (CTLs), is an important component for enhancing the clinical response of cancer immunotherapy. Hence, we explored a novel method for preparing cancer-specific CTLs using naive T lymphocytes. Methods C57BL/6 mice bearing B16 melanoma tumors were pretreated with cyclophosphamide (CTX) by peritoneal injection. The immunosuppressive influence of CTX on tumor regression and the tumor microenvironment was assessed. Naive T cells and T cell pools were isolated via negative selection using immunomagnetic beads. The proliferative potential and cytokine production of different T cell subpopulations were evaluated in vitro. Tumor-specific CTLs derived from naive T cells (naive CD4+ T cells: naive CD8+ T cells=2:1) and pooled T cells were generated in vitro, respectively. B16 melanoma-bearing C57BL/6 mice were pretreated with CTX, followed by ACT immunotherapy using dendritic cell-induced CTLs. The homing abilities of the effector cells and interleukin-2 (IL-2), interferon-gamma, granzyme B, and perforin mRNA levels in tumor tissues were evaluated, and the change in tumor volume was measured. Results Mice receiving CTX peritoneal pretreatment injections did not display tumor regression compared with control mice. However, a significant downregulation of splenic Tregs and tumor growth factor-beta 1 (TGF-beta 1) and interleukin-10 (IL-10) serum levels was observed (P<0.05). Naive T cells showed a stronger proliferative capacity and elevated cytokine production than did pooled T cells (P<0.05). In addition, effector cells generated from naive T cells displayed more potent antitumor activity in vivo than those derived from pooled T cells (P<0.05). Conclusion Effector cells derived from the naive T cells possess a stronger proliferative potential, homing capacity, and enhanced cytokine production, which leads to a superior antitumor response.
引用
收藏
页码:1328 / 1333
页数:6
相关论文
共 50 条
  • [1] Effector cells derived from naive T cells used in tumor immunotherapy of mice bearing B16 melanoma
    Wen Ming
    Xu Weili
    Ren Lili
    Gao Fei
    Cui Naipeng
    Wen Junye
    Li Xinjiang
    Lin Lin
    Ma Zhenfeng
    Chen Baoping
    Cai Jianhui
    中华医学杂志(英文版), 2014, (07) : 1328 - 1333
  • [2] Adoptive Transfer of Tumor-Specific Tc17 Effector T Cells Controls the Growth of B16 Melanoma in Mice
    Garcia-Hernandez, Maria de la Luz
    Hamada, Hiromasa
    Reome, Joyce B.
    Misra, Sara K.
    Tighe, Michael P.
    Dutton, Richard W.
    JOURNAL OF IMMUNOLOGY, 2010, 184 (08): : 4215 - 4227
  • [3] CHARACTERIZATION OF EFFECTOR-CELLS AGAINST B16 MELANOMA IN MICE INOCULATED WITH ALLOGENEIC SPLEEN-CELLS
    NISHI, Y
    HOSOKAWA, T
    AOIKE, A
    HAN, D
    TAKEHARA, H
    KAWAI, K
    KAMAHORA, T
    MICROBIOLOGY AND IMMUNOLOGY, 1994, 38 (03) : 217 - 223
  • [4] Immunotherapy of metastases with lymphocytes treated with exogenous RNA in mice bearing B16 melanoma
    Watanabe, MAE
    Almeida, DO
    Serrano, SV
    Sales, VSF
    Soares, FA
    DeLucca, FL
    CELLULAR AND MOLECULAR BIOLOGY, 1997, 43 (03) : 393 - 398
  • [5] METASTATIC PHENOTYPE IN HYBRID-CELLS DERIVED FROM B16 MELANOMA
    ITO, M
    IZUHARA, M
    SHIMIZU, K
    SEKIGUCHI, M
    CANCER LETTERS, 1994, 78 (1-3) : 33 - 39
  • [6] Efficacy of B16 melanoma cells exposed in vitro to long-term IFN-α treatment (B16α cells) as a tumor vaccine in mice
    Wu, TY
    Fleischmann, WR
    JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 1998, 18 (10): : 829 - 839
  • [7] LUNG-COLONY ASSAY - EXTENSION TO LEWIS LUNG TUMOR AND B16 MELANOMA - RADIOSENSITIVITY OF B16 MELANOMA CELLS
    HILL, RP
    STANLEY, JA
    INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 1975, 27 (04) : 377 - 387
  • [8] Platelet mediated adhesion of tumor cells promotes metastasis of B16 melanoma cells
    Lonsdorf, A. S.
    Enk, A. H.
    Langer, H. F.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2009, 129 : S36 - S36
  • [9] B16 melanoma cells exposed in vitro to long-term IFN-alpha treatment (B16 alpha cells) as activators of tumor immunity in mice
    Fleischmann, CM
    Wu, TY
    Fleischmann, WR
    JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 1997, 17 (01): : 37 - 43
  • [10] SUPPRESSOR CELLS IN MICE BEARING B-16 MELANOMA
    STELZER, GT
    WALLACE, JH
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1977, 18 (MAR): : 68 - 68